$2.99 Billion is the total value of Redmile Group, LLC's 74 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 43.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Sell | AMICUS THERAPEUTICS INC | $182,777,000 | -35.7% | 22,790,134 | -0.0% | 6.12% | -24.0% |
| EPZM | Sell | EPIZYME INC | $89,090,000 | -18.7% | 8,636,933 | -1.1% | 2.98% | -3.8% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $83,221,000 | -26.0% | 2,962,655 | -0.3% | 2.78% | -12.5% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $68,440,000 | -9.0% | 1,160,401 | -0.5% | 2.29% | +7.6% |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $63,818,000 | -31.0% | 4,519,717 | -1.8% | 2.14% | -18.4% |
| KRYS | Sell | KRYSTAL BIOTECH INC | $37,444,000 | -13.9% | 1,078,300 | -0.2% | 1.25% | +1.8% |
| XNCR | Sell | XENCOR INC | $29,670,000 | -55.1% | 879,627 | -45.5% | 0.99% | -46.8% |
| TCRR | Sell | TCR2 THERAPEUTICS INC | $26,908,000 | +4.5% | 1,790,288 | -0.5% | 0.90% | +23.5% |
| GRTS | Sell | GRITSTONE ONCOLOGY INC | $26,807,000 | -25.2% | 3,104,494 | -3.5% | 0.90% | -11.5% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $26,490,000 | +18.3% | 1,164,402 | -0.4% | 0.89% | +40.0% |
| SRRK | Sell | SCHOLAR ROCK HLDG CORP | $25,574,000 | -44.8% | 2,857,389 | -2.2% | 0.86% | -34.7% |
| LIVN | Sell | LIVANOVA PLC | $25,309,000 | -17.0% | 342,987 | -19.1% | 0.85% | -1.9% |
| STOK | Sell | STOKE THERAPEUTICS INC | $21,866,000 | -26.6% | 1,017,478 | -0.4% | 0.73% | -13.2% |
| AXNX | Sell | AXONICS MODULATION TECH INC | $21,797,000 | -34.6% | 809,700 | -0.5% | 0.73% | -22.7% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $15,953,000 | -29.0% | 3,115,865 | -0.7% | 0.53% | -16.0% |
| BCEL | Sell | ATRECA INC | $13,943,000 | -35.1% | 1,139,106 | -0.1% | 0.47% | -23.2% |
| ADPT | Sell | ADAPTIVE BIOTECHNOLOGIES COR | $13,102,000 | -36.2% | 424,000 | -0.2% | 0.44% | -24.6% |
| GLYC | Sell | GLYCOMIMETICS INC | $8,610,000 | -64.0% | 1,997,647 | -0.5% | 0.29% | -57.5% |
| LOGC | Sell | LOGICBIO THERAPEUTICS INC | $8,097,000 | -23.6% | 749,026 | -8.1% | 0.27% | -9.7% |
| CMRX | Sell | CHIMERIX INC | $7,604,000 | -50.5% | 3,235,795 | -9.1% | 0.25% | -41.6% |
| OVID | Sell | OVID THERAPEUTICS INC | $395,000 | -71.0% | 121,950 | -83.5% | 0.01% | -66.7% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $211,000 | -99.4% | 971 | -99.3% | 0.01% | -99.3% |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -22,236 | -100.0% | -0.01% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -254,590 | -100.0% | -0.04% | – |
| AVDR | Exit | AVEDRO INC | $0 | – | -216,200 | -100.0% | -0.12% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -39,900 | -100.0% | -0.14% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -97,191 | -100.0% | -0.24% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCcall | $0 | – | -100,000 | -100.0% | -0.24% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -375,375 | -100.0% | -0.25% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -188,000 | -100.0% | -0.28% | – |
| PSNL | Exit | PERSONALIS INC | $0 | – | -400,000 | -100.0% | -0.31% | – |
| MOR | Exit | MORPHOSYS AGsponsored ads | $0 | – | -733,699 | -100.0% | -0.50% | – |
| OXFD | Exit | OXFORD IMMUNOTEC GLOBAL PLC | $0 | – | -1,796,477 | -100.0% | -0.70% | – |
| TDOC | Exit | TELADOC HEALTH INC | $0 | – | -461,880 | -100.0% | -0.87% | – |
| Exit | ARRAY BIOPHARMA INCnote 2.625%12/0 | $0 | – | -16,500,000 | -100.0% | -1.42% | – | |
| ANTM | Exit | ANTHEM INC | $0 | – | -183,500 | -100.0% | -1.46% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -412,000 | -100.0% | -1.77% | – |
| EHTH | Exit | EHEALTH INC | $0 | – | -888,705 | -100.0% | -2.16% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -8,752,254 | -100.0% | -11.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.